Black Diamond’s lung cancer pivot delivers

It is rare for the scrapping of a pipeline lead to bring about a corporate turnaround just one year later, but this is the trick Black Diamond Therapeutics pulled off yesterday. First clinical data on its new lead, BDTX-1535, drove the stock up 236%, to levels not seen since October 2021.